Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer
Center for Life Sciences · BGI Group (China) · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
60
total citations
- FWCI
- 47.12
- Percentile
- 100%
- References
- 130
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Lenvatinib
- Cytotoxic T cell
- Cancer
- Cancer research
- Medicine
- Oncology
- Immunology
- Biology
No related works found for this paper.
Funding
- IRInnovative Research Team of High-level Local University in Shanghai
- NNNational Natural Science Foundation of ChinaAwards: 82272803, 31991170, 82122049, 31821003, 31991173, 31900636, 82341011
- CAChinese Academy of Meteorological SciencesAward: 2022-I2M-5-01
- NKNational Key Research and Development Program of ChinaAwards: 2022YFA0912600, 2021YFC2302403
- SSShenzhen Science and Technology Innovation ProgramAward: RCJC20231211085947070